218 related articles for article (PubMed ID: 16943541)
1. Immunotherapy and prognostic factors.
Fumagalli LA; Brivio F
J Clin Oncol; 2006 Sep; 24(25):4218-9; author reply 4219-20. PubMed ID: 16943541
[No Abstract] [Full Text] [Related]
2. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer.
Parton M; Gore M; Eisen T
J Clin Oncol; 2006 Dec; 24(35):5584-92. PubMed ID: 17158544
[TBL] [Abstract][Full Text] [Related]
3. Survival in renal cell carcinoma: a randomized evaluation of tamoxifen vs interleukin-2, alpha-interferon (leucocyte) and tamoxifen.
Huland E; Heinzer H
Br J Cancer; 2000 Jan; 82(1):246-7. PubMed ID: 10638997
[No Abstract] [Full Text] [Related]
4. [First-line therapy for German patients with metastatic kidney neoplasms in EORTC-Protocol 30012].
Rexer H
Urologe A; 2004 Aug; 43(8):992-3. PubMed ID: 15316609
[No Abstract] [Full Text] [Related]
5. Prediction of response to combined immunotherapy with interferon-alpha and low-dose interleukin-2 in metastatic renal cell carcinoma: expression patterns of potential molecular markers in radical nephrectomy specimens.
Miyake H; Sakai I; Muramaki M; Kurahashi T; Takenaka A; Fujisawa M
Int J Urol; 2009 May; 16(5):465-71. PubMed ID: 19467119
[TBL] [Abstract][Full Text] [Related]
6. Temsirolimus for advanced renal-cell carcinoma.
Ferretti G
N Engl J Med; 2007 Sep; 357(10):1050; author reply 1050-1. PubMed ID: 17823993
[No Abstract] [Full Text] [Related]
7. Immunotherapy for metastatic renal cell carcinoma.
McDermott DF; Rini BI
BJU Int; 2007 May; 99(5 Pt B):1282-8. PubMed ID: 17441925
[No Abstract] [Full Text] [Related]
8. Re: C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy.
Ramsey S; Aitchison M
J Urol; 2005 Dec; 174(6):2422-3. PubMed ID: 16280863
[No Abstract] [Full Text] [Related]
9. Tumor infiltrating dendritic cells predict treatment response to immmunotherapy in patients with metastatic renal cell carcinoma.
Kobayashi M; Suzuki K; Yashi M; Yuzawa M; Takayashiki N; Morita T
Anticancer Res; 2007; 27(2):1137-41. PubMed ID: 17465253
[TBL] [Abstract][Full Text] [Related]
10. [Interferon-based cytokine therapy for advanced renal cell carcinoma].
Takayama T; Kai F; Sugiyama T; Furuse H; Mugiya S; Ozono S
Hinyokika Kiyo; 2005 Aug; 51(8):499-502. PubMed ID: 16164263
[TBL] [Abstract][Full Text] [Related]
11. [Influence of immunological parameters on the effectiveness of systemic and loco-regional immunotherapy in disseminated renal carcinoma].
Granov AM; Molchanov OE; Karelin MI; Shkol'nik MI; Krotova OA
Vopr Onkol; 2009; 55(5):580-5. PubMed ID: 20020653
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors for renal cell carcinoma with tumor thrombus extension.
Klatte T; Pantuck AJ; Riggs SB; Kleid MD; Shuch B; Zomorodian N; Kabbinavar FF; Belldegrun AS
J Urol; 2007 Oct; 178(4 Pt 1):1189-95; discussion 1195. PubMed ID: 17698087
[TBL] [Abstract][Full Text] [Related]
13. Progressive anemia following combination therapy with interferon-alpha and interleukin-2 in a patient with metastatic renal cell carcinoma.
Hosokawa Y; Kishino T; Ono T; Oyama N; Hayashi K; Momose H
Int J Urol; 2004 Oct; 11(10):906-8. PubMed ID: 15479299
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
15. Randomized study of intravenous versus subcutaneous interleukin-2, and IFNalpha in patients with good prognosis metastatic renal cancer.
Négrier S; Perol D; Ravaud A; Bay JO; Oudard S; Chabaud S; Fargeot P; Delva R; Deplanque G; Gravis G; Escudier B;
Clin Cancer Res; 2008 Sep; 14(18):5907-12. PubMed ID: 18794104
[TBL] [Abstract][Full Text] [Related]
16. High-dose interleukin-2 may not be superior to low-dose interleukin-2 plus interferon.
Alikhan M; Spencer HJ; Kohli M
J Clin Oncol; 2005 Sep; 23(25):6267-8; author reply 6268-9. PubMed ID: 16135500
[No Abstract] [Full Text] [Related]
17. Predicting survival of patients with metastatic renal cell carcinoma.
Motzer RJ; Mazumdar M
Urologe A; 2004 Sep; 43 Suppl 3():S135-6. PubMed ID: 15148574
[TBL] [Abstract][Full Text] [Related]
18. Metastatic renal cell carcinoma: systemic treatment.
Abi-Aad AS; deKernion JB
Acta Urol Belg; 1996 May; 64(2):3-8. PubMed ID: 8701805
[No Abstract] [Full Text] [Related]
19. The MRC randomised-controlled trial of interferon-alpha, interleukin-2 and 5-fluorouracil vs interferon-alpha alone in patients with advanced renal cell carcinoma (RE04): rationale and progress.
Larkin JM; Gore ME
Clin Oncol (R Coll Radiol); 2005 Aug; 17(5):319-21. PubMed ID: 16097560
[No Abstract] [Full Text] [Related]
20. Chronically administered immunotherapy with low-dose IL-2 and IFN-alpha in metastatic renal cell carcinoma: a feasible option for patients with a good prognostic profile.
Vaglio A; Alberici F; Maggiore U; Buti S; Potenzoni D; Passalacqua R; Buzio C
Oncology; 2009; 76(1):69-76. PubMed ID: 19047813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
